Your browser doesn't support javascript.
loading
Cardiac allograft vasculopathy and donor age affecting permanent pacemaker implantation after heart transplantation.
Roest, Stefan; Manintveld, Olivier C; Kolff, Marit A E; Akca, Ferdi; Veenis, Jesse F; Constantinescu, Alina A; Brugts, Jasper J; Birim, Ozcan; van Osch-Gevers, Lennie M; Szili-Torok, Tamas; Caliskan, Kadir.
Affiliation
  • Roest S; Department of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
  • Manintveld OC; Erasmus MC Transplant Institute, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
  • Kolff MAE; Department of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
  • Akca F; Erasmus MC Transplant Institute, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
  • Veenis JF; Department of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
  • Constantinescu AA; Erasmus MC Transplant Institute, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
  • Brugts JJ; Department of Cardiothoracic Surgery, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
  • Birim O; Department of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
  • van Osch-Gevers LM; Department of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
  • Szili-Torok T; Erasmus MC Transplant Institute, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
  • Caliskan K; Department of Cardiology, Thorax Center, Erasmus MC, University Medical Centre Rotterdam, Rotterdam, The Netherlands.
ESC Heart Fail ; 9(2): 1239-1247, 2022 04.
Article in En | MEDLINE | ID: mdl-35174653
ABSTRACT

AIMS:

The need for permanent pacemakers (PMs) after heart transplantation (HT) is increasing. The aim was to determine the influence of cardiac allograft vasculopathy (CAV), donor age, and other risk factors on PM implantations early and late after HT and its effect on survival. METHODS AND

RESULTS:

A retrospective, single-centre study was performed including HTs from 1984 to July 2018. Early PM was defined as PM implantation ≤90 days and late PM as PM > 90 days. Risk factors for PM and survival after PM were determined with (time-dependent) multivariable Cox regression. Out of 720 HTs performed, 62 were excluded (55 mortalities ≤30 days and 7 retransplantations). Of the remaining 658 patients, 95 (14%) needed a PM 38 (6%) early and 57 (9%) late during follow-up (median 9.3 years). Early PM risk factors were donor age [hazard ratio (HR) 1.06, P < 0.001], ischaemic time (HR 1.01, P < 0.001), and in adults amiodarone use before HT (HR 2.02, P = 0.045). Late PM risk factors were donor age (HR 1.03, P = 0.024) and CAV (HR 3.59, P < 0.001). Late PM compromised survival (HR 2.05, P < 0.001), while early PM did not (HR 0.77, P = 0.41).

CONCLUSIONS:

Risk factors for early PM implantation were donor age, ischaemic time, and in adults amiodarone use before HT. Late PM implantation risk factors were donor age and CAV. Late PM diminished survival, which is probably a surrogate marker for underlying progressive cardiac disease.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pacemaker, Artificial / Heart Transplantation / Heart Diseases Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: ESC Heart Fail Year: 2022 Document type: Article Affiliation country: Países Bajos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pacemaker, Artificial / Heart Transplantation / Heart Diseases Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Humans Language: En Journal: ESC Heart Fail Year: 2022 Document type: Article Affiliation country: Países Bajos